文献速递糖尿病肥胖与代谢综合征

MASLD的遗传学:糖尿病视角

Genetics of MASLD: a diabetes perspective.
PubMed 文献 · Diabetologia · 2026-06-08

本文综述了2型糖尿病背景下MASLD的遗传结构。全基因组关联研究已发现多个影响肝脏脂肪积累、疾病严重程度和进展的遗传位点,涉及肝内脂质处理缺陷、肝脏脂肪生成增强及胰岛素抵抗相关系统代谢障碍等机制。遗传证据表明相似程度的肝脂肪变可能反映不同生物学过程,对血糖管理、心血管风险和肝病进展有不同影响。

要点

  • MASLD在2型糖尿病中高发,但临床病程异质性大,传统代谢危险因素不能完全解释。
  • 全基因组关联研究已识别多个影响肝脂肪积累、严重程度和进展的遗传位点。
  • 遗传证据支持基于机制框架理解糖尿病中MASLD异质性,助力风险分层和精准管理。

核心结论

  • 当前遗传证据支持基于机制框架理解糖尿病中MASLD异质性,为更精准的风险评估和管理奠定基础。

研究设计与样本

  • 综述,整合家族研究、全基因组关联分析、影像遗传学和孟德尔随机化证据,强调谨慎的因果解释。

主要发现

  • 全基因组关联研究已识别多个影响肝脏脂肪积累、疾病严重程度和进展的遗传位点。
  • 这些位点涉及肝内脂质处理缺陷、肝脏脂肪生成增强及胰岛素抵抗和脂肪组织生物学相关系统代谢障碍。
  • 相似程度的肝脂肪变可能反映不同生物学过程,对血糖管理、心血管风险和肝病进展有不同影响。

临床怎么用

  • 遗传信息可用于MASLD风险分层、治疗靶点发现和新兴的基因型指导临床管理方法。

局限性

  • 需要 ancestry-diverse 研究、改进糖尿病人群表型分析,并将遗传分析整合到前瞻性临床试验中。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Metabolic dysfunction-associated steatotic liver disease (MASLD) is highly prevalent in people with type 2 diabetes and represents a major contributor to liver-related and extrahepatic morbidity and mortality. Despite this strong epidemiological overlap, the clinical course of MASLD in diabetes is highly heterogeneous and not fully explained by conventional metabolic risk factors. Human genetic studies have provided important insights into this variability by revealing that hepatic steatosis and its downstream consequences can arise through biologically distinct pathways. Genome-wide association studies have identified multiple genetic loci influencing liver fat accumulation, disease severity and progression. These loci implicate diverse mechanisms, including liver-intrinsic defects in lipid handling, enhanced hepatic lipogenesis, and systemic metabolic dysfunction related to insulin resistance and adipose tissue biology. Genetic evidence indicates that similar degrees of hepatic steatosis may therefore reflect different underlying biological processes, with differing implications for glycaemic management, cardiovascular risk and liver disease progression. In this review, we examine the genetic architecture of hepatic steatosis and MASLD in the context of diabetes. We discuss evidence from family studies, genome-wide association analyses, imaging genetics and Mendelian randomisation, with an emphasis on cautious causal interpretation. We also explore gene-diabetes and gene-environment interactions that modify disease expression and may contribute to variability in clinical outcomes and treatment response. Finally, we consider the translational implications of MASLD genetics, including risk stratification, therapeutic target discovery and emerging genotype-informed approaches to clinical management. We highlight key research gaps, particularly the need for ancestry-diverse studies, improved phenotyping in diabetes populations, and integration of genetic analyses into prospective clinical trials. Together, current genetic evidence supports a mechanism-based framework for understanding MASLD heterogeneity in diabetes and provides a foundation for more precise approaches to risk assessment and management.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Bilson J, Yaghootkar H. Genetics of MASLD: a diabetes perspective. Diabetologia. 2026. PMID: 42257871. doi:10.1007/s00125-026-06759-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。